ARA 290
ARA-290 (Cibinetide) is a revolutionary 11-amino-acid peptide surgically derived from Erythropoietin (EPO). However, its structure was precisely truncated to completely eliminate EPO's dangerous stimulation of red blood cell production. It is the absolute gold standard for combatting catastrophic sensory damage, specifically utilized in elite protocols to aggressively reverse profound small-fiber neuropathy, heal crushed peripheral nerves, and stop systemic, treatment-resistant pain syndromes.
Quick Stats
Scientific Data
Mechanism of Action
ARA 290 (Cibinetide) is a non-hematopoietic synthetic peptide mimic of erythropoietin (EPO), engineered to selectively activate the innate repair receptor (IRR) — a heterodimer of the EPO receptor and CD131 — without stimulating erythropoiesis or EPO's hematopoietic effects.
IRR activation suppresses pro-inflammatory cytokine production, promotes axonal regeneration, and has demonstrated efficacy in small-fiber neuropathy and painful diabetic peripheral neuropathy. ARA 290 has completed Phase II trials showing improvements in corneal nerve regeneration, neuropathic pain scores, and inflammatory markers in diabetic neuropathy patients.
Source: PMID: 25074880
Background & History
ARA 290 (Cibinetide) was developed by Araim Pharmaceuticals based on research by Anthony Cerami and Michael Brines. The key insight: erythropoietin (EPO) has tissue-protective effects mediated through a different receptor than the one driving erythropoiesis. ARA 290 was designed to specifically target this "innate repair receptor" (EPOR/βcR heterodimer) without stimulating red blood cell production. This allows EPO's neuroprotective, anti-inflammatory, and tissue-regenerative effects at pharmacological doses without the dangerous polycythemia that limits therapeutic EPO use.
Research Use Cases
- ✓Neuropathy treatment (sarcoidosis, diabetic peripheral)
- ✓Tissue protection and repair after ischemic events
- ✓Anti-inflammatory therapy without immunosuppression
- ✓Neuroprotection in chronic inflammatory conditions
Dosing Protocol
| Typical Dose | 1-4 mg SC |
| Frequency | 1× daily or 3× weekly |
| Half-Life | ~2 minutes |
| Common Vial Sizes | 4 mg, 8 mg |
Dosing Protocols
Phase II Protocol (Neuropathy)
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 1000–4000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 771 mcg | 1929 mcg | 3086 mcg |
| 140 lb(63 kg) | 900 mcg | 2250 mcg | 3600 mcg |
| 160 lb(73 kg) | 1043 mcg | 2607 mcg | 4171 mcg |
| 180 lb(82 kg) | 1171 mcg | 2929 mcg | 4686 mcg |
| 200 lb(91 kg) | 1300 mcg | 3250 mcg | 5200 mcg |
| 220 lb(100 kg) | 1429 mcg | 3571 mcg | 5714 mcg |
| 250 lb(113 kg) | 1614 mcg | 4036 mcg | 6457 mcg |
💉 For exact syringe units based on your vial concentration, use the ARA 290 Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Neuropathy / Peripheral Nerve Repair
LowPhase II data for small-fiber neuropathy and DPN. Promotes axonal regeneration via IRR activation.
Inflammatory Conditions
LowAnti-inflammatory via IRR-mediated cytokine suppression. Not EPO-related blood thickening concerns.
Reconstitution Example
Safety & Considerations
Phase II clinical compound. Does not stimulate erythropoiesis (no red blood cell increase). Well-tolerated in trials. No significant adverse events reported.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Very short half-life (~2 minutes) — effects mediated through signaling cascades that outlast peptide presence. No erythropoietic stimulation — can be used where EPO is contraindicated. Completed Phase II trials with favorable safety. No significant drug interactions documented.
Synergies & Common Stacks
ARA 290 (systemic tissue protection via innate repair receptor) complements BPC-157 (local tissue repair via growth factor modulation) — multi-pathway tissue regeneration.
Both promote tissue repair through different mechanisms — ARA 290 via innate repair receptor, TB-500 via actin sequestration and cell migration. Complementary wound healing and tissue regeneration.
Dosing Quick Reference
Frequently Asked Questions
Is ARA 290 the same as EPO?▼
References
- Brines M et al. “"ARA290 improves neurological and metabolic indicators in small fiber neuropathy".” Acta Diabetologica (2014). PMID: 24609842
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code